Skip to content

Study · Not a test of the peptide alone · 2026

12 results

Ultrasound-propelled oncolytic biomimetic microbubbles as in situ vaccines reprogram tumor immunosuppressive microenvironment.

Wan L, Liang P, Xia C, Yu L, Tang R, Li X, Tang C, Wu N, Huang Z, Chen J, Fu R, Jiao M, Hu J, Li P, Li R

Materials today. Bio11 Feb 2026

PMID41756527 (opens in a new tab)PMCIDPMC12933863 (opens in a new tab)DOI10.1016/j.mtbio.2026.102923 (opens in a new tab)PepBankPUB-41756527
Read at sourcePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

  1. 01AnimalNot a test of LTX-315 aloneOther designPharmacokinetics

    In tumor models, LCMBs enabled targeted delivery and ultrasound-responsive release of LTX‑315 at the tumor site.

    In plain wordsIn tumor models, microbubbles enabled targeted delivery and ultrasound-triggered release of LTX‑315.

    Peptide
    LTX-315
    Outcome
    Not applicableTumor delivery and release
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The LCMBs enabled the targeted delivery and stimuli-responsive release of LTX-315 in the tumor site under low-intensity focused ultrasound (US).
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  2. 02AnimalNot a test of LTX-315 aloneOther designActivity measurement

    In tumor models, LTX‑315 accumulation and ultrasound-mediated membrane permeabilization lowered the therapeutic threshold of LTX‑315.

    In plain wordsIn tumor models, LTX‑315 accumulation and ultrasound-mediated membrane changes lowered its treatment threshold.

    Peptide
    LTX-315
    Outcome
    DecreaseTherapeutic threshold
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The high accumulation of LTX-315 and sonoporation-mediated membrane permeabilization collectively lowered the therapeutic threshold of LTX-315, improving oncolytic efficacy and reducing the off-target toxicity.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  3. 03AnimalNot a test of LTX-315 aloneOther designEfficacy outcome

    In tumor models, LTX‑315 accumulation with ultrasound-mediated membrane permeabilization improved oncolytic efficacy.

    In plain wordsIn tumor models, LTX‑315 accumulation with ultrasound-mediated membrane changes improved cancer cell killing.

    Peptide
    LTX-315
    Outcome
    IncreaseOncolytic efficacy
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The high accumulation of LTX-315 and sonoporation-mediated membrane permeabilization collectively lowered the therapeutic threshold of LTX-315, improving oncolytic efficacy and reducing the off-target toxicity.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  4. 04AnimalNot a test of LTX-315 aloneOther designSafety outcome

    In tumor models, LTX‑315 accumulation with ultrasound-mediated membrane permeabilization reduced off-target toxicity.

    In plain wordsIn tumor models, the LTX‑315 delivery approach reduced toxicity outside the target.

    Peptide
    LTX-315
    Outcome
    DecreaseOff-target toxicity
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    The high accumulation of LTX-315 and sonoporation-mediated membrane permeabilization collectively lowered the therapeutic threshold of LTX-315, improving oncolytic efficacy and reducing the off-target toxicity.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  5. 05AnimalNot a test of LTX-315 aloneOther designMechanism

    In tumor models, delivered LTX‑315 potentiated rapid membrane lysis.

    In plain wordsIn tumor models, delivered LTX‑315 increased rapid membrane breakdown.

    Peptide
    LTX-315
    Outcome
    IncreaseMembrane lysis
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    LTX-315 further potentiated rapid membrane lysis and subsequent immunogenic cell death, promoting the release of tumor antigens, forming an in situ vaccine, and boosting the activation of T cells.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  6. 06AnimalNot a test of LTX-315 aloneOther designMechanism

    In tumor models, delivered LTX‑315 potentiated immunogenic cell death.

    In plain wordsIn tumor models, delivered LTX‑315 increased cell death that stimulates immunity.

    Peptide
    LTX-315
    Outcome
    IncreaseImmunogenic cell death
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    LTX-315 further potentiated rapid membrane lysis and subsequent immunogenic cell death, promoting the release of tumor antigens, forming an in situ vaccine, and boosting the activation of T cells.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  7. 07AnimalNot a test of LTX-315 aloneOther designMechanism

    In tumor models, delivered LTX‑315 promoted tumor antigen release.

    In plain wordsIn tumor models, delivered LTX‑315 promoted tumor antigen release.

    Peptide
    LTX-315
    Outcome
    IncreaseTumor antigen release
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    LTX-315 further potentiated rapid membrane lysis and subsequent immunogenic cell death, promoting the release of tumor antigens, forming an in situ vaccine, and boosting the activation of T cells.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  8. 08AnimalNot a test of LTX-315 aloneOther designMechanism

    In tumor models, delivered LTX‑315 boosted T-cell activation.

    In plain wordsIn tumor models, delivered LTX‑315 increased T-cell activation.

    Peptide
    LTX-315
    Outcome
    IncreaseT-cell activation
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    LTX-315 further potentiated rapid membrane lysis and subsequent immunogenic cell death, promoting the release of tumor antigens, forming an in situ vaccine, and boosting the activation of T cells.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  9. 09AnimalNot a test of LTX-315 aloneOther designMechanism

    In tumor models, LCMBs plus anti-PD-1 therapy elicited robust anticancer immune responses.

    In plain wordsIn tumor models, LTX‑315 microbubbles plus anti-PD-1 therapy stimulated anticancer immune responses.

    Peptide
    LTX-315
    Outcome
    Not applicableAnticancer immune response
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    After being combined with anti-programmed death-1 (αPD-1) therapy, the integrated LCMBs + αPD-1 regimen elicited robust anticancer immune responses, so the primary tumor, tumor recurrence, and distant metastasis were notably restrained.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  10. 10AnimalNot a test of LTX-315 aloneOther designEfficacy outcome

    In tumor models, LCMBs plus anti-PD-1 therapy restrained primary tumors.

    In plain wordsIn tumor models, LTX‑315 microbubbles plus anti-PD-1 therapy restrained primary tumors.

    Peptide
    LTX-315
    Outcome
    DecreasePrimary tumor
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    After being combined with anti-programmed death-1 (αPD-1) therapy, the integrated LCMBs + αPD-1 regimen elicited robust anticancer immune responses, so the primary tumor, tumor recurrence, and distant metastasis were notably restrained.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  11. 11AnimalNot a test of LTX-315 aloneOther designEfficacy outcome

    In tumor models, LCMBs plus anti-PD-1 therapy restrained tumor recurrence.

    In plain wordsIn tumor models, LTX‑315 microbubbles plus anti-PD-1 therapy restrained tumor recurrence.

    Peptide
    LTX-315
    Outcome
    DecreaseTumor recurrence
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    After being combined with anti-programmed death-1 (αPD-1) therapy, the integrated LCMBs + αPD-1 regimen elicited robust anticancer immune responses, so the primary tumor, tumor recurrence, and distant metastasis were notably restrained.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  12. 12AnimalNot a test of LTX-315 aloneOther designEfficacy outcome

    In tumor models, LCMBs plus anti-PD-1 therapy restrained distant metastasis.

    In plain wordsIn tumor models, LTX‑315 microbubbles plus anti-PD-1 therapy restrained distant tumor spread.

    Peptide
    LTX-315
    Outcome
    DecreaseDistant metastasis
    Study

    n: not reported in source

    tumor models with ultrasound-propelled LTX-315-loaded microbubbles
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    After being combined with anti-programmed death-1 (αPD-1) therapy, the integrated LCMBs + αPD-1 regimen elicited robust anticancer immune responses, so the primary tumor, tumor recurrence, and distant metastasis were notably restrained.
    1 context sentence
    Summary · context
    Herein, we innovatively engineered an ultrasound-propelled cancer cell membranes-hybridized lipid microbubbles to load oncolytic peptide LTX-315 (LCMBs) for precise and controlled oncolytic therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.